
Head of the Russian Government Dmitri Medvedev visited today CJSC BIOCAD's commercial manufacturing facility for mAb-based therapeutic proteins.  This private facility is unique in Russia and Easter Europe. It produces monoclonal antibodies-based APIs for biological products that are widely used in treating oncological and autoimmune disorders.  The visit occurred in the context of the Presidium's meeting of the Russian Presidential Council on Innovations and Modernization. The focus of this meeting was on innovative developments in medical equipment and pharmaceutical industry.

The company currently employs over 700 people, 150 of whom are researchers and investigators working at BIOCAD's labs. BIOCAD 2013 sales were close to $ 90 m. The company has subsidiaries and representation in Belarus, Brazil, China, India, Ukraine, and the U.S.

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

Browse our custom packages or build your own to meet your unique communications needs.

Request more information about PR Newswire products and services or call us at (888) 776-0942.
